Overview

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study was to compare the rate and extent of absorption of Purepac, a subsidiary of Alpharma Inc., U.S.A., galantamine and Janssen Pharmaceutica Products, L.P., U.S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Actavis Inc.

Treatments:

Galantamine